The Role of Medication Abortion Provision in US States Without Total Abortion Bans, 2023.

IF 3.5 2区医学 Q1 DEMOGRAPHY Perspectives on Sexual and Reproductive Health Pub Date : 2025-03-01 Epub Date: 2025-02-10 DOI:10.1111/psrh.12294

Isabel DoCampo, Rachel K Jones, Isaac Maddow-Zimet

{"title":"The Role of Medication Abortion Provision in US States Without Total Abortion Bans, 2023.","authors":"Isabel DoCampo, Rachel K Jones, Isaac Maddow-Zimet","doi":"10.1111/psrh.12294","DOIUrl":null,"url":null,"abstract":"Background: Medication abortion has accounted for an increasing share of abortions in the United States (US) since the Food and Drug Administration's approval of mifepristone in 2000. This study offers updated estimates of medication abortions provided within the formal healthcare system in 2023 in US states without total abortion bans as well as a discussion of recent trends in medication abortion provision.Methods: The Guttmacher Institute's Monthly Abortion Provision Study employs data from monthly samples of providers in a Bayesian hierarchical model to produce estimates of abortions provided within the formal healthcare system. We estimate the number and share of medication abortions provided in 2023 in states without total abortion bans and the share of abortions provided through telemedicine-only clinics.Results: Clinicians provided 648,500 medication abortions within the formal healthcare system in 2023 in states without total bans (90% uncertainty interval: 640,720-657,860), representing 63% of all abortions. Ten percent of all abortions were provided by telemedicine-only clinics. The number of medication abortions provided in US states without total abortion bans increased by 19% between 2019 and 2020, and by 32% between 2020 and 2023.Discussion: Medication abortion plays a critical role in the US abortion access landscape. Medication abortion provision has accelerated since 2019, likely due to COVID-era policies that facilitated the expansion of telemedicine medication abortion provision. This shift has created essential access for individuals navigating abortion bans and other barriers to care since the removal of federal abortion protections.","PeriodicalId":47632,"journal":{"name":"Perspectives on Sexual and Reproductive Health","volume":" ","pages":"3-7"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936859/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perspectives on Sexual and Reproductive Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/psrh.12294","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DEMOGRAPHY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Medication abortion has accounted for an increasing share of abortions in the United States (US) since the Food and Drug Administration's approval of mifepristone in 2000. This study offers updated estimates of medication abortions provided within the formal healthcare system in 2023 in US states without total abortion bans as well as a discussion of recent trends in medication abortion provision.

Methods: The Guttmacher Institute's Monthly Abortion Provision Study employs data from monthly samples of providers in a Bayesian hierarchical model to produce estimates of abortions provided within the formal healthcare system. We estimate the number and share of medication abortions provided in 2023 in states without total abortion bans and the share of abortions provided through telemedicine-only clinics.

Results: Clinicians provided 648,500 medication abortions within the formal healthcare system in 2023 in states without total bans (90% uncertainty interval: 640,720-657,860), representing 63% of all abortions. Ten percent of all abortions were provided by telemedicine-only clinics. The number of medication abortions provided in US states without total abortion bans increased by 19% between 2019 and 2020, and by 32% between 2020 and 2023.

Discussion: Medication abortion plays a critical role in the US abortion access landscape. Medication abortion provision has accelerated since 2019, likely due to COVID-era policies that facilitated the expansion of telemedicine medication abortion provision. This shift has created essential access for individuals navigating abortion bans and other barriers to care since the removal of federal abortion protections.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

药物流产条款在没有完全禁止堕胎的美国各州的作用，2023。

背景：自2000年美国食品和药物管理局批准米非司酮以来，药物流产在美国流产中所占的比例越来越大。本研究提供了2023年美国各州正式医疗保健系统内没有全面禁止堕胎的药物流产的最新估计，并讨论了药物流产提供的最新趋势。方法：古特马赫研究所的每月堕胎提供研究采用了贝叶斯层次模型中每月提供者样本的数据，以产生在正规医疗保健系统内提供的堕胎估计。我们估计了2023年在没有完全禁止堕胎的州提供的药物堕胎的数量和份额，以及通过远程医疗诊所提供的堕胎份额。结果：2023年，在没有全面禁令的州，临床医生在正式医疗保健系统内提供了648,500例药物流产（90%不确定区间：640,720-657,860），占所有流产的63%。10%的堕胎是由远程医疗诊所提供的。在没有全面禁止堕胎的美国各州，药物流产的数量在2019年至2020年期间增加了19%，在2020年至2023年期间增加了32%。讨论：药物流产在美国堕胎准入中起着关键作用。自2019年以来，药物流产服务加速增长，这可能是由于新冠疫情时期的政策促进了远程医疗药物流产服务的扩大。自从取消联邦堕胎保护以来，这种转变为个人绕过堕胎禁令和其他障碍获得护理创造了必要的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Perspectives on Sexual and Reproductive Health Multiple-

CiteScore

5.10

自引率

3.40%

发文量

期刊介绍： Perspectives on Sexual and Reproductive Health provides the latest peer-reviewed, policy-relevant research and analysis on sexual and reproductive health and rights in the United States and other developed countries. For more than four decades, Perspectives has offered unique insights into how reproductive health issues relate to one another; how they are affected by policies and programs; and their implications for individuals and societies. Published four times a year, Perspectives on Sexual and Reproductive Health includes original research, special reports and commentaries on the latest developments in the field of sexual and reproductive health, as well as staff-written summaries of recent findings in the field.